Alpha emitter radium-223 and survival in metastatic prostate cancer

New England Journal of Medicine

Volumn 369, Issue 3, 2013, Pages 213-223

  Parker, Christopher ^a   Nilsson D Heinrich, S ^i,n   Helle, S I ^o   O'Sullivan, J M ^b   Fossa S D ^p   Chodacki, A ^u   Wiechno, P ^v   Logue, J ^c   Seke, M ^j   Widmark, A ^k   Johannessen, D C ^q   Hoskin, P ^d   Bottomley, D ^e   James, N D ^f   Solberg, A ^t   Syndikus, I ^g   Kliment, J ^w   Wedel, S ^x   Boehmer, S ^y   Dall'Oglio, M ^z   Franzen L ^l,m   Coleman, R ^h   Vogelzang, N J ^aa   O'Bryan Tear, C G ^r   Staudacher, K ^r   Garcia Vargas, J ^ab   Shan, M ^ab   Bruland, O S ^s   Sartor, O ^ac   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d MOUNT VERNON CANCER CENTRE   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^g CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^h WESTON PARK HOSPITAL   (United Kingdom)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j Centrallasarettet   (Sweden)

^k UMEÅ UNIVERSITY   (Sweden)

^l UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^m Sundsvall Härnösand County Hospital   (Sweden)

ⁿ AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^o HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^p OSLO UNIVERSITY HOSPITAL   (Norway)

^q ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^r Algeta ASA   (Norway)

^s UNIVERSITY OF OSLO   (Norway)

^t TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^u Hospital Kochova   (Czech Republic)

^v INSTITUTE OF ONCOLOGY   (Poland)

^w Martinska Fakultna Nemocnica   (Slovakia)

^x Klinikum Offenburg   (Germany)

^y Gemeinschaftspraxis   (Germany)

^z UNIVERSITY OF SÃO PAULO   (Brazil)

^aa Department of Hematology Oncology   (United States)

^ab BAYER CORPORATION   (United States)

^ac TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; RADIUM 223; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GENERAL CONDITION DETERIORATION; HEMATOLOGIC DISEASE; HEMATURIA; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPINAL CORD COMPRESSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URINE RETENTION; VOMITING; WEIGHT REDUCTION;

EID: 84880428467     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1213755     Document Type: Article

References (34)

1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
3. Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 1998-1999;17:331-6.
4. Lipton A. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 2010;37:Suppl 2:S15-S29.
5. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997;80:Suppl:1674-9. (Pubitemid 27444040)
6. Silberstein EB. Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol 2000;10:240-9. (Pubitemid 30452639)
7. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71.
8. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet 2011;377:813-22.
9. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005;6:392-400. (Pubitemid 40753745)
10. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005;46:Suppl 1:38S-47S. (Pubitemid 47619017)
11. Sartor O. Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer. Asian J Androl 2011;13:366-8.
12. Sartor O, Bruland O. Stromal targeted therapies in prostate and renal cancer: new concepts and knowledge. Clin Genitourin Cancer 2011;9:1-2.
13. Sartor O, Goeckeler W, Bruland O. Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. Asian J Androl 2011;13:783-4.
14. Bruland ØS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12:6250s-6257s. (Pubitemid 44703798)
15. Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø, Larsen RH. Significant antitumor effect from bone-seeking, alphaparticle- emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120-5. (Pubitemid 34605984)
16. Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003;44:252-9.
17. Liepe K. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Investig Drugs 2009;10:1346-58.
18. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25:1341-51. (Pubitemid 28446064)
19. Kerr C. (223)Ra targets skeletal metastases and spares normal tissue. Lancet Oncol 2002;3:453. (Pubitemid 34863657)
20. Li Y, Russell PJ, Allen BJ. Targeted al-pha- therapy for control of micrometastatic prostate cancer. Expert Rev Anticancer Ther 2004;4:459-68. (Pubitemid 38745117)
21. Nilsson S, Larsen RH, Fosså SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451-9. (Pubitemid 40834252)
22. Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587-94. (Pubitemid 46995621)
23. Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra-223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013;63:189-97.
24. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012;48:678-86.
25. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
26. Cella D, Nichol MB, Eton D, et al. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy-Prostate: results from a clinical trial of patients with metastatic hormonerefractory prostate cancer. Value Health 2009;12:124-9.
27. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
28. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56. (Pubitemid 10242750)
29. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
30. Perlroth DJ, Thompson SF, Luna Y, et al. Timing is everything: time to ADT and chemotherapy initiation for treatment of metastatic prostate cancer (mPC). Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, February 2-4, 2012 (poster).
31. Perlroth DJ, Thompson SF, Mozaffari E, et al. Treating people right: who goes untreated with systemic therapy for metastatic prostate cancer (mPC)? Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, February 2-4, 2012 (poster).
32. Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population-based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011;23:706-8.
33. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
34. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.